Evidence-based treatments for gastrointestinal diseases
We are building a pipeline of evidence-based gastrointestinal health products, through in-house development and in-licencing / partnership opportunities.
We’re delighted to share that Stage 1 of the GaRP Irritable Bowel Syndrome (IBS) trial has reached its conclusion.
Our commitment to improving lives through research is stronger than ever.
Irritable Bowel Syndrome (IBS) is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care.
Anatara Lifesciences (ASX: ANR) specialises in creating evidence-based, innovative products to address unmet needs in gastrointestinal health for both humans and animals. Our focus is on building a pipeline of gastrointestinal health products through our own research and development as well as strategic partnerships. Our core commitment is to deliver tangible benefits to patients and create significant value for our shareholders.
Anatara Lifesciences is developing evidence based solutions for gastrointestinal diseases in humans and animals. Click below to discover more about our innovative approaches, cutting-edge technologies, and our mission to make a meaningful impact on gastrointestinal health.